{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T05:19:09Z","timestamp":1787635149699,"version":"build-2736575974"},"reference-count":0,"publisher":"International Union Against Tuberculosis and Lung Disease","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["int j tuberc lung dis"],"published-print":{"date-parts":[[2025,9,26]]},"abstract":"\n <sec><title>BACKGROUND<\/title>New chemotherapeutic agents are needed for the treatment of drug-resistant\n Mycobacterium tuberculosis<\/jats:italic>\n (MTB),\n M. avium<\/jats:italic>\n complex (MAC),\n M. abscessus<\/jats:italic>\n (MAB), and\n M. kansasii<\/jats:italic>\n (MKN) lung diseases. We tested epetraborole,\n a novel leucyl-tRNA synthetase (LeuRS) inhibitor, against four pathogenic mycobacteria.<\/sec><sec><title>METHODS<\/title>Reference and clinical strains were used in static concentration-response and minimum inhibitory concentration (MIC) studies. Data were used\n to calculate cumulative MIC for 50% of isolates (MIC\n 50<\/jats:sub>\n ), MIC\n 90<\/jats:sub>\n , and concentration mediating 50% of maximal effect (EC\n 50<\/jats:sub>\n ).<\/sec><sec><title>RESULTS<\/title>Epetraborole microbial kill (log\n 10<\/jats:sub>\n CFU\/ml) below day 0 bacterial\n burden was 0.37 \u00b1 0.33 for MAB, 2.59 \u00b1 0.06 for MAC, 1.49 \u00b1 0.02 for MKN, and 0.51 \u00b1 0.0 for MTB. Epetraborole EC\n 50<\/jats:sub>\n , in mg\/L, was 0.19 \u00b1 0.03 for MAB, 0.28 \u00b1 0.02 for MAC, 0.54 \u00b1 0.06 for MKN, and 0.43 \u00b1 0.86 for MTB. Epetraborole\n MIC\n 50<\/jats:sub>\n and MIC\n 90<\/jats:sub>\n were 0.25 and 0.5 mg\/L for MAB (n = 59), respectively. For MAC, epetraborole MIC\n 50<\/jats:sub>\n and MIC\n 90<\/jats:sub>\n were 2 and 16 mg\/L for\n M. avium<\/jats:italic>\n (n = 17) and were 4 and 8 mg\/L for\n M. intracellulare<\/jats:italic>\n (n = 26), respectively. For MKN (n = 20),\n epetraborole MIC\n 50<\/jats:sub>\n and MIC\n 90<\/jats:sub>\n were 16 mg\/L. For MTB (n = 21), MIC\n 50<\/jats:sub>\n and MIC\n 90<\/jats:sub>\n were 2 and 8 mg\/L respectively.<\/sec><sec><title>CONCLUSION<\/title>Epetraborole MICs and EC\n 50<\/jats:sub>\n s were lowest for MAB while the best\n kill was with MAC. Systematic pharmacokinetic\/pharmacodynamic studies are warranted for non-tuberculous mycobacteria and MTB.<\/sec>\n <\/jats:p>","DOI":"10.5588\/ijtld.25.0097","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T16:34:05Z","timestamp":1766075645000},"page":"447-454","source":"Crossref","is-referenced-by-count":1,"title":["Mycobacteria susceptibility to epetraborole: how far can it go?"],"prefix":"10.5588","volume":"29","author":[{"given":"S.","family":"Singh","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, University of Texas at Tyler School of Medicine, Tyler, TX, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.D.","family":"Boorgula","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, University of Texas at Tyler School of Medicine, Tyler, TX, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.-A.","family":"Galvez","sequence":"additional","affiliation":[{"name":"Department of Medicine, Section of Pulmonary and Critical Care, University of Texas at Tyler School of Medicine, Tyler, TX, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.K.","family":"Heysell","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and International Health, University of Virginia, Charlottesville, VA, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.J.","family":"McShane","sequence":"additional","affiliation":[{"name":"Department of Medicine, Section of Pulmonary and Critical Care, University of Texas at Tyler School of Medicine, Tyler, TX, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Devine","sequence":"additional","affiliation":[{"name":"Department of Medicine, Section of Pulmonary and Critical Care, University of Texas at Tyler School of Medicine, Tyler, TX, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Gumbo","sequence":"additional","affiliation":[{"name":"IMPI Biotech Consortium Inc., Tateguru, Zimbabwe;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Srivastava","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, University of Texas at Tyler School of Medicine, Tyler, TX, USA;, Department of Cellular and Molecular Biology, The University of Texas Health Science Centre at Tyler, Tyler, TX, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3554","container-title":["The International Journal of Tuberculosis and Lung Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/iuatld\/ijtld\/2025\/00000029\/00000010\/art00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T04:31:08Z","timestamp":1787632268000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.5588\/ijtld.25.0097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":0,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,9,26]]}},"alternative-id":["1027-3719(20250926)29:10L.447;1-"],"URL":"https:\/\/doi.org\/10.5588\/ijtld.25.0097","relation":{},"ISSN":["1027-3719"],"issn-type":[{"value":"1027-3719","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,26]]}}}